B01: Predicting response to venetoclax/azacitidine in AML by determining cytologic variability in AML blasts with generative AI image analysis combined with single-celltranscriptomics

Project B01 will analyze variability of AML blasts as determinants of response to venetoclax and azacytidine treatment. Advanced multiomics scRNA-Seq and generative AI- based image analysis will be applied to paired primary samples (diagnosis/relapse) to integrate cellular morphology with molecular analyses in order to predict treatment outcomes and to identify novel VEN/AZA response biomarkers.